Patents by Inventor Matthew N. Meriggioli

Matthew N. Meriggioli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REGULATION OF APOPTOSIS BY NEURAL SPECIFIC SPLICE VARIANTS OF IG20
    Publication number: 20110117627
    Abstract: Pro-apoptotic signaling caused by down-modulation of KIAA0358 or expression of IG20-SV4 effectively induces spontaneous apoptosis and sensitization to TNF?-induced apoptosis in neuroblastoma cells. Methods and composition to enhance cell death in neuroblastoma are provided. Methods and compositions to reduce cell death in neurodegenerative disorders are provided.
    Type: Application
    Filed: July 10, 2009
    Publication date: May 19, 2011
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Bellur S. Prabhakar, Matthew N. Meriggioli, Liang Cheng LI
  • USES OF BISPECIFIC ANTIBODY COATED DENDRITIC CELLS PULSED WITH ANTIGENS AND GM-CSF IN IMMUNE REGULATION
    Publication number: 20090232854
    Abstract: GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG.
    Type: Application
    Filed: March 10, 2009
    Publication date: September 17, 2009
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Bellur S. Prabhakar, Mark J. Holterman, Chenthamarakshan Vasu, Matthew N. Meriggioli
  • Uses of bispecific antibody coated dendritic cells pulsed with antigens and GM-CSF in immune regulation
    Patent number: 7527972
    Abstract: GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: May 5, 2009
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Bellur S. Prabhakar, Mark J. Holterman, Chenthamarakshan Vasu, Matthew N. Meriggioli